In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MediStem Inc.

Latest From MediStem Inc.

Strong Market For Regenerative Medicine Deals Drives Value

Untapped market opportunities for treating and possibly curing underserved diseases have spurred an active deal-making environment in regenerative medicine, according to a new report from Datamonitor Healthcare.

Regenerative Medicine Deals

APPOINTMENTS: Valeant, Gilead, Editas, Daiichi, Scancell, PhaseRx, Clintec, Acadia

This week’s announcements include Valeant’s appointment of an executive vice president finance, Editas Medicine’s appointment of a chief scientific officer, Clintec’s appointment of AstraZeneca’s former global research director and various board appointments by Acadia, Scancell, PhaseRx and Gilead.

Executive Changes BioPharmaceutical

Batu Biologics names new chair

Batu Biologics, a San Diego biotechnology company developing cancer angiogenesis-targeting immunotherapeutic product ValloVax, has named Dr Alan Lewis as chair of its board of directors. Dr Lewis has previously been vice-president of research at Wyeth-Ayerst, and CEO at Signal Pharmaceuticals, Novocell, and the Juvenile Diabetes Research Foundation. Most recently he was CEO of Medistem, where he worked with Batu Biologics co-founder Dr Thomas Ichim.

Metabolic Disorders Cancer

Deals Shaping The Medical Industry, February 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2013 through January 2014.

BioPharmaceutical Medical Device
See All

Company Information